Dr. George W. Carr, MD
Family Medicine (Family Medicine Physician)
1241 W Stadium Blvd
Jefferson City, MO 65109
Who else practices at this address →
Cole County is a federal primary care and dental shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Missouri, Columbia School of Medicine (1985)
- Years since graduation
- 41
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 363
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1985Medical school: University of Missouri, Columbia School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
MO license 36781
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Missouri Health Care Columbia, MO
- Lake Regional Health System Osage Beach, MO
- Ssm Health St. Mary's Hospital - Jefferson City Jefferson City, MO
Medical groups
- Jefferson City Medical Group PC (119 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 363
- Services billed
- 11,179
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 622 | 267 |
| Insertion of needle into vein for collection of blood sample | 431 | 251 |
| Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | 302 | 225 |
| Established patient office or other outpatient visit, 20-29 minutes | 258 | 219 |
| Blood test, thyroid stimulating hormone (tsh) | 248 | 219 |
| Thyroxine (thyroid chemical), free | 245 | 216 |
| Blood test, basic group of blood chemicals (calcium, total) | 230 | 172 |
| Hemoglobin a1c level | 209 | 132 |
| Blood test, lipids (cholesterol and triglycerides) | 207 | 180 |
| Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | 199 | 199 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 33 companies reported 189 payments worth $3,093 in total to this clinician.
| AbbVie Inc. | $547 |
|---|---|
| Pfizer Inc. | $537 |
| Novo Nordisk Inc | $380 |
| Amgen Inc. | $164 |
| Dexcom, Inc. | $145 |
| Bayer HealthCare Pharmaceuticals Inc. | $141 |
| Lilly USA, LLC | $129 |
| Lundbeck LLC | $116 |
| Food and Beverage | $2,977 |
|---|---|
| Education | $116 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Lundbeck LLC Aug 28, 2025 | Education REXULTI · PSYCHIATRY · in-kind | $38.54 |
| Lundbeck LLC Oct 30, 2025 | Education REXULTI · PSYCHIATRY · in-kind | $38.54 |
| Lundbeck LLC Dec 16, 2025 | Education REXULTI · PSYCHIATRY · in-kind | $38.54 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 11 industry-funded studies in 2025, from 8 companies. The companies reported $266,053 in research payments for these studies, mostly to the institutions running them.
- A randomized, double-blind, placebo-controlled, multicenter, dose range finding study, to evaluate efficacy, safety and pharmacodynamics of QCZ484 in mild to moderate hypertensive patients
Novartis Pharmaceuticals Corporation - A Phase III, Randomised, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Effect of AZD0780 on Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Diseas…
AstraZeneca Pharmaceuticals LP - A Phase III Randomised Double Blind PlaceboControlled Parallel Group Study to Assess the Effect of AZD0780 on Low Density Lipoprotein Cholesterol in Patients With Elevated Low Density Lipoprotein Cholesterol and Clini…
AstraZeneca Pharmaceuticals LP - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
Boehringer Ingelheim Pharmaceuticals, Inc. - A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in p…
Boehringer Ingelheim Pharma GmbH & Co.kg - A Phase I-III Randomized Double blind Study to Evaluate the Safety and Neutralizing Activity of AZD5156-AZD3152 for Pre exposure Prophylaxis of COVID 19 in Participants with Conditions Causing Immune Impairment
AstraZeneca UK Limited - A phase 3,global,randomized,modified double blind,placebo controlled,study to evaluate the efficacy,immunogenicity,and safety of IVX A12,a respiratory syncytial virus RSV and human metapneumovirus hMPV virus like part…
AstraZeneca Pharmaceuticals LP - Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)
Alnylam Pharmaceuticals Inc. - A Study to Evaluate Efficacy and Safety of ALN-AGT01 in Patients With Mild To-Moderate Hypertension (KARDIA-1)
Alnylam Pharmaceuticals Inc. - A phase 1/2, randomized, observer-blinded, multi-country study to eval
GlaxoSmithKline, LLC.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.